TABLE 5

Treatment at last follow-up

SyncopeAVT+AVTNon-syncopeAVT+AVTp-value (syncope versus non-syncope)
Subjects n421428671453
CCB for vasoresponsiveness10 (24)10#06 (6)6#00.03
CCB monotherapy3 (6)303 (3)300.67
Single PAH therapy6 (14)4218 (27)5130.12
Dual PAH therapy13 (31)31011 (16)1100.07
Triple PAH therapy18 (43)31523(34)3210.37
No medication2 (4)1112 (18)2100.046
IV/SQ prostanoid20 (48)1 (7)19+ (68)15 (22)1 (7)14 (26)0.006

Data are expressed as n or n (%). Bold p-values represent statistically significant differences between patients with and without syncope. AVT: acute vasodilator testing; CCB: calcium channel blocker; PAH: pulmonary arterial hypertension; IV: intravenous; SQ: subcutaneous. #: p for AVT+ versus AVT <0.00001; : p for AVT+ versus AVT <0.05 (for syncope CCB only, p=0.03; for syncope triple PAH therapy, p=0.047; for non-syncope CCB only, p=0.007); +: p for AVT+ versus AVT =0.0002.